FORUM Pharmaceuticals

Boston hosts Biopharm America

Tuesday, September 15, 2015

Biopharm America, which is designed to spur strategic relationships by way of a Web-based service that sets up face-to-face meetings and more, kicks off today in Boston with more than 450 companies, 680 delegates and 770 licensing opportunities on the roster.

[Read More]

FORUM Pharmaceuticals receives FDA Fast Track for schizophrenia

Thursday, June 25, 2015

The FDA has granted Fast Track designation to encenicline, FORUM Pharmaceuticals’ lead compound in development to treat cognitive impairment in schizophrenia. Encenicline is a novel alpha 7 agonist in phase III development by FORUM to treat cognitive impairment in schizophrenia and Alzheimer’s disease. The company recently completed patient enrollment in its pivotal phase III COGNITIV SZ clinical trial program investigating the use of encenicline as a pro-cognitive therapy in patients with schizophrenia who are currently being treated with atypical antipsychotics.

[Read More]

Forum Pharmaceuticals relocates headquarters to Waltham, Massachusetts

Wednesday, May 20, 2015

Forum Pharmaceuticals, a biopharmaceutical company focused on the development and delivery of innovative medicines to treat serious brain diseases, has relocated its corporate headquarters to a 112,500-square-foot, state-of-the-art facility located in Waltham, Mass. The move consolidates Forum’s operations into a single centralized location that houses corporate offices, clinical development and research laboratories. Previously, Forum conducted business from two locations in Watertown, Mass. and Brighton, Mass. The company also maintains a small European office in the Netherlands.

[Read More]